Mythili Ramachandran

Title: Innovations of Mythili Ramachandran

Introduction

Mythili Ramachandran is a notable inventor based in Columbia, MO (US). She has made significant contributions to the field of biochemistry, particularly in the development of peptides with specific binding affinities. Her work is characterized by a focus on innovative solutions that enhance detection methods in medical applications.

Latest Patents

Mythili Ramachandran holds a patent for a peptide with gold binding and EGFR receptor affinity, which is attached to a gold nanostructure. The invention includes a peptide comprising four domains, where domain I consists of thioctyl or monocytl, domain II consists of 2 to 3 positively charged amino acids selected from lysine and arginine, domain III consists of a dimeric ethylene unit, and domain IV comprises the peptide with SEQ ID No. 1 or a sequence having at least 90% identity to SEQ ID No. 1. This peptide is preferably attached to a gold nanostructure, specifically a gold nanorod, to provide an EGFR detection kit. The kit employs a gold nanostructure attached to a peptide sequence that includes a binding sequence with an affinity toward EGFR, a ligand bound to gold atoms of the nanorod, a positively charged amino acid that maintains the activity of the binding sequence, and a unit that increases the hydrophilicity of the peptide sequence. She has been granted 1 patent for this innovative work.

Career Highlights

Mythili Ramachandran is affiliated with the University of Missouri, where she continues to advance her research in biochemistry and peptide technology. Her academic background and research initiatives have positioned her as a key figure in her field.

Collaborations

Mythili has collaborated with notable colleagues, including Charles W Caldwell, Jr. and Raghuraman Kannan. These collaborations have further enriched her research and contributed to the development of her innovative projects.

Conclusion

Mythili Ramachandran's contributions to peptide technology and her innovative patent demonstrate her commitment to advancing medical detection methods. Her work continues to inspire future research in the field.